A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Subcutaneously Administered REGN475 in Patients With Sciatic Pain.
Phase of Trial: Phase II
Latest Information Update: 01 Dec 2011
At a glance
- Drugs Fasinumab (Primary)
- Indications Sciatica
- Focus Therapeutic Use
- 16 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 May 2010 Interim results have been reported in a Regneron Pharmaceuticals media release.
- 25 Mar 2010 Planned end date changed from Aug 2010 to May 2010 as reported by ClinicalTrials.gov.